Drugging the microbiome and bacterial live biotherapeutic consortium production
Research leading to characterization, quantification, and functional attribution of the microbes throughout the human body has led to many drug-development programs. These programs aim to manipulate a patient’s microbiome through the addition of new strains or functions, the subtraction of deleterio...
Gespeichert in:
Veröffentlicht in: | Current opinion in biotechnology 2022-12, Vol.78, p.102801-102801, Article 102801 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Research leading to characterization, quantification, and functional attribution of the microbes throughout the human body has led to many drug-development programs. These programs aim to manipulate a patient’s microbiome through the addition of new strains or functions, the subtraction of deleterious microbes, or the rebalancing of the existing population through various drug modalities. Here, we present a general overview of those modalities with a specific focus on bacterial live biotherapeutic products (LBPs). The bacterial LBP modality has unique concerns to ensure product quality, thus, topics related to manufacturing, quality control, and regulation are addressed.
[Display omitted]
•Microbiomes represent new drug targets for pharmaceutical development.•‘Dysbiosis’ describes poor composition or species balance, contributing to disease.•Live biotherapeutic products (LBPs) are an enriching class of microbiome therapies.•Manufacture leverages vaccine experience but must be adapted for commensal strains.•Variety of LBPs require per-product assessment of required quality elements. |
---|---|
ISSN: | 0958-1669 1879-0429 |
DOI: | 10.1016/j.copbio.2022.102801 |